21
May

08:30 AM PDT

Drug Discovery Biology

Name: Drug Discovery Biology & Bioinformatics Strategy Meeting West Coast USA 2024
Start: 2024-05-21T08:00
End: 2024-05-21T18:00
Location: Hard Rock Hotel San Diego

&

Bioinformatics

Strategy Meeting West Coast USA 2024

Assessing, Choosing And Optimizing The Right Set Of Data And Methodologies To Help With Finding Effective Modalities And Techniques For Biology

Hard Rock Hotel San Diego

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Biology Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Biology professionals from across the West Coast, in San Diego, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the West Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at Drug Discovery Biology & Bioinformatics strategy meeting.

Adam Marko

Life Sciences Field CTO Hammerspace

Adam Mullick

Vice President, Cardiovascular Drug Discovery Ionis Pharma

Anastasia Velentza

Former Senior Director, Head of Discovery Technology Plexium

Angela Huang

Founder and President Tempo Bioscience

Amish Patel

Senior Vice President Technical Operations Calidi Biotherapeutics

Dr. Amish Patel has over 20 years of leadership experience in the global biotech industry, providing strategic guidance throughout the entire biologic product life-cycle and been involved with fifteen+ INDs and commercial product launch. Dr. Patel is responsible for oversight of Global Manufacturing, Quality Control, Quality Assurance and Supply Chain to produce Clinical and Commercial cancer therapies utilizing Calidi’s innovative oncolytic viral therapies with stem cell-based delivery platforms to treat cancers with significant unmet needs. Dr Patel has managed the CDMO network and supplied clinical products for phase 1 and phase 3 trials globally. Dr Patel has extensive experience in licensing and out licensing several technologies from Academia and non profit organizations and even commercialized such assets. He serves as Technical Activities Committee of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) part of Manufacturing USA® and funded through the U.S. Department of Commerce with significant additional support from its members. He was most recently, the Senior Director of Product Development at Emergent BioSolutions (formerly PaxVax, Inc., prior to acquisition), where he successfully built and directed cross-functional teams working on numerous biologic Clinical and commercial products.

Bishnu Nayak

Senior Director/Site Head Neologics Bio

Dimitra Chalkia

Vice President, Computational Biology Athos Therapeutics

Frederick Chang

CEO Kekulai

Geza Ambrus-Aikelin

Head of Immunology & Inflammation Genesis Therapeutics

Igor Nasonkin

Co-founder & CEO Phythera Therapeutics

Igor Nasonkin is a Founder, Director, and Principal Investigator, with 9 years in industry (Phythera Therapeutics, Lineage Cell Therapeutics, Biotime, Bresagen) and 24 years in academia (UPitt, NIH, JHU, MIT, UM, UBC). He specialized in small molecule-based therapies modulating neurodegenerative diseases and cancer, botanical-based drugs for cancer therapeutics, cell & gene therapies (retina, brain), stem cell-based therapies, and building new projects and teams from the ground up. Igor has extensive experience in building and leading several productive & cohesive research teams, conceptualizing new ideas and research directions, grant writing (NIH, DOD, CIRM, foundation grants), manuscript writing, drafting patent applications, sponsored projects agreements, and business plans. He has written for a variety of Scientific reviewers (several journals), while being a member of the Editorial Board (several journals). His successfully funded SBIR grants include: 5R44EY027654 09/30/2017-5/31/2019; 3 R44 EY 027654-02 S1 06/01/2019-05/31/2020

Joan Chen, PhD

Senior Director of Bioinformatics, Precision Medicine and Translational Research Boundless Bio

Joan Chen, PhD, has over 16 years of experience in the biopharma industry, with a focus on oncology for the past ten years. She has led many drug discovery, translational research programs and helped advance a number of drug candidates from preclinical research into the clinical trials. Dr. Chen’s expertise in drug development includes target identification and validation, designing studies for mechanisms of action, pharmacodynamic response (both preclinical and clinical), machine learning and NGS data analysis in biomarker discoveries, generating disease hypotheses for patient selections in clinical trials. Dr. Chen holds a PhD in Molecular, Cell and Development Biology with a specialization in bioinformatics from UCLA. She was a Bioinformatics Senior Scientist at eFFECTOR Therapeutics; Director of Bioinformatics at Certis Oncology; Research Fellow at Turning Point Therapeutics (acquired by BMS in 2022), and currently Senior Director at Boundless Bio.

John Leonard

Chief Executive Officer Aeona Pharmaceuticals

Molly Presley

SVP Global Marketing Hammerspace

Philip Cheung

Founder and Chief Executive Officer Refactor Biosciences

Sanjeev Thohan

Scientific Advisory Board Member Cogentis Therapeutics/ Phoenix Molecular Designs

Salah Mahmoudi

Co-Founder and Chief Executive Officer ReneuBio

Stephanie Truhlar

Associate Vice President Eli Lilly

Zev Wisotsky

Director, Drug Discovery New Modality Solutions Revvity Signals

OUR AGENDA

See Which Topics Are Up For Discussion

08:30 – 09:00

The enhanced botanical drugs for Cancer Therapeutics

Igor Nasonkin, Co-founder & CEO, Phythera Therapeutics

09:00 – 10:00

Roundtable Tracks

Target Identification & Hit Validation
Navigating the Complexities of Target Identification and Hit Validation in Drug Discovery

-Bishnu Nayak
Senior Director/Site Head
Neologics Bio

DMPK / ADME & Toxicology & In Vivo and In Vitro Pharmacology
Optimizing Drug Development From PK Profiles To Novel Therapeutic Interventions

-Sanjeev Thohan
Scientific Advisory Board Member
Cogentis Therapeutics/ Phoenix Molecular Designs

In Silico Biology / AI & ML
Discussing empirical methods in instituting a data-driven drug discovery

-Salah Mahmoudi
Co-Founder and Chief Executive Officer
ReneuBio

Bioinformatics / Data Integration & Data Mining
Leveraging AI protein folding models for drug discovery

-Frederick Chang
CEO
Kekulai

Strategic Partnerships, Investment & Collaborations
Considering Contemporary Techniques In Adapting Go To Market Approach

-John Leonard
Chief Executive Officer
Aeona Pharmaceuticals

11:10 – 12:10

Roundtable Tracks

Target Identification & Hit Validation
From Selection to Validation: Exploring Strategies for Target Identification and Validation

-Anastasia Velentza
Former Senior Director, Head of Discovery Technology
Plexium

DMPK / ADME & Toxicology & In Vivo and In Vitro Pharmacology
Integrating Breakthroughs In In Silico, In Vivo And In Vitro Pharmacology To Enhance ADMET Modeling

SPONSOR

In Silico Biology / AI & ML
Leveraging AI, Target Selection Technologies / Strategies And Infrastructure Tools To Support Computational Biology

SPONSOR

Bioinformatics / Data Integration & Data Mining
Unifying data access and high-performance data platforms

-Adam Marko
Life Sciences Field CTO
Hammerspace

HAMMERSPACE

Strategic Partnerships, Investment & Collaborations
Harnessing the Power of Data: Integrating Bioinformatics, Chemistry Informatics, and AI for Next-Generation Solutions

-Zev Wisotsky
Director, Drug Discovery New Modality Solutions
Revvity Signals

Revvity Signals

12:15 – 13:15

Roundtable Tracks

Target Identification & Hit Validation
Challenges of disease modeling and target discovery: how best to equip our drug hunters with the tools to be successful?

-Adam Mullick
Vice President, Cardiovascular Drug Discovery
Ionis Pharma

DMPK / ADME & Toxicology & In Vivo and In Vitro Pharmacology
Drug target validation during discovery and preclinical development stages: What, Why and How

-Yuhua Ji
Vice President, Drug Discovery
Grace Science, LLC

In Silico Biology / AI & ML
Evaluating Practical Uses Of Latest AI/ML Tools To Expedite And Increase Efficiency In Drug Discovery Process

-Stephanie Truhlar
Associate Vice President
Eli Lilly

Bioinformatics / Data Integration & Data Mining
Setting fundamentals in data democratization and the factors to consider in making it happen

-Philip Cheung
Founder and Chief Executive Officer
Refactor Biosciences

Strategic Partnerships, Investment & Collaborations
Leveraging On Academic Partnerships To Further Drug Discovery And Development Operations

-Amish Patel
Senior Vice President Technical Operations
Calidi Biotherapeutics

14:40 – 15:10

Architecting for the Future: Cutting Edge Best Practices for Optimizing Data Pipelines

Afternoon Keynote Presentation PRESENTER: Molly Presley, SVP Global Marketing, Hammerspace

15:10 – 16:10

Roundtable Tracks

Target Identification & Hit Validation
Target Validation And Small Molecule Hit Identification In The Era Of Modern Drug Discovery

-Geza Ambrus-Aikelin
Head of Immunology & Inflammation
Genesis Therapeutics

DMPK / ADME & Toxicology & In Vivo and In Vitro Pharmacology
Latest Approaches and Trends For Improving Nonclinical Studies

-Angela Huang
Founder and President
Tempo Bioscience

In Silico Biology / AI & ML
Navigating The Latest Machine Learning Tools For In Silico Drug Discovery And Its Contribution In Accelerating Drug Discovery Process

-Dimitra Chalkia
Vice President, Computational Biology
Athos Therapeutics

Bioinformatics / Data Integration & Data Mining
Introducing Cutting-Edge Bioinformatics Applications In Novel Therapeutic Areas

-Joan Chen, PhD
Senior Director of Bioinformatics, Precision Medicine and Translational Research
Boundless Bio

Strategic Partnerships, Investment & Collaborations
How to effectively leverage collaboration with academics in drug discovery programs

-Yuhua Ji
Vice President, Drug Discovery
Grace Science, LLC

16:30 – 17:00

Tackling The Pros And Cons Of Different Financing Blueprint Go-To-Clinic Vs Go-To-Market Vs Go-To-Fundraising Strategies And The Criteria To Determine Which Program An Organization Can Adapt

PANELIST: Sanjeev Thohan, Scientific Advisory Board Member, Cogentis Therapeutics/Phoenix Molecular Designs PANELIST: Philip Cheung, Chief Executive Officer, Refactor Biosciences PANELIST: Yuhua Ji, VP of Drug Discovery, Grace Science

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D San Diego

Drug Discovery Biology & Bioinformatics Strategy Meeting West Coast USA 2024

&

Strategy Meeting West Coast USA 2024

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Hard Rock Hotel San Diego

Fresh Biology Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our Facilitators

Adam Marko

Adam Mullick

Anastasia Velentza

Angela Huang

Amish Patel

Bishnu Nayak

Dimitra Chalkia

Frederick Chang

Geza Ambrus-Aikelin

Igor Nasonkin

Joan Chen, PhD

John Leonard

Molly Presley

Philip Cheung

Sanjeev Thohan

Salah Mahmoudi

Stephanie Truhlar

Zev Wisotsky

OUR AGENDA

See Which Topics Are Up For Discussion

Breakfast & Registration

Opening Keynote Presentation

The enhanced botanical drugs for Cancer Therapeutics

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Refreshment Break

Networking/1-1 Meetings

Roundtable ( Solutions )

Roundtable Tracks

SPONSOR

SPONSOR

HAMMERSPACE

Revvity Signals

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Networking Lunch

Networking/1-1 Meetings

Afternoon Keynote Presentation

Architecting for the Future: Cutting Edge Best Practices for Optimizing Data Pipelines

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Afternoon Refreshment Break

Panel Discussion

Tackling The Pros And Cons Of Different Financing Blueprint Go-To-Clinic Vs Go-To-Market Vs Go-To-Fundraising Strategies And The Criteria To Determine Which Program An Organization Can Adapt

Drinks & Canapes Reception

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our 2024 Sponsors

Thought Leader

Partnering Sponsors

Key Opinion Leader

Media Partners

Press play to hear what your colleagues had to say…

Hotel & Venue

Hard Rock Hotel San Diego

Want to find out more?

Here To Help

Hard Rock Hotel San Diego